Vertex developed a CRISPR cure. It’s already on the hunt for something better.
The company that just got approval to sell the first gene-editing treatment in history, for sickle-cell disease, is already looking for an ordinary drug that could take its place. Vertex Pharmaceuticals has a 50-person team working “to make a pill that doesn’t do gene editing at all,” says David Altshuler, head of research at the…
https://www.technologyreview.com/2023/12/15/1085380/vertex-sickle-cell-pill-treatment/